|
|
|
Journalists
Press releases
Press releases 2008
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Press releases are intended to journalists, analysts and investors.
DIONYSOS study results showed the respective profiles of dronedarone and amiodarone
December 23, 2008
Sanofi-aventis and Novozymes announce a development and commercialization collaboration for an innovative antibiotic
December 22, 2008
INTANZA® / IDflu®, first intradermal influenza vaccine recommended in the European Union
December 18, 2008
Board of Directors dated December 17, 2008 - Corporate Governance
December 18, 2008
Sanofi-aventis was granted the 2008 China Charity Award by the Ministry of Civil Affairs of the People’s Republic of China
December 15, 2008
Sanofi-aventis and Bristol-Myers Squibb prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® patent infringement case
December 12, 2008
Changes in organisation
December 10, 2008
Results of a phase III trial on Elitek® presented at ASH Annual Meeting
December 7, 2008
Chris Viehbacher takes up his position as Chief Executive Officer
December 1, 2008
FDA intends to have an Advisory Committee meeting for Multaq® (dronedarone) on March 18, 2009
November 27, 2008
Sanofi-aventis Europe’s recommended Offer for Zentiva to remain open until February 20, 2009
November 26, 2008
Sanofi-aventis announces the settlement of Nasacort® AQ U.S. patent litigation and certain Allegra®/Allegra® D-12 U.S. patent litigations
November 19, 2008
Russia chooses inactivated Polio vaccine from Sanofi Pasteur for primary immunization of all infants
November 12, 2008
Dronedarone (Multaq®) reduced the incidence and duration of hospitalization in patients with atrial fibrillation
November 11, 2008
Sanofi Pasteur first international vaccine company to enter Japan with pediatric vaccine
November 10, 2008
Publication in the American Heart Journal of CURRENT-OASIS 7 trial design
November 6, 2008
Sanofi-aventis to discontinue all clinical trials with rimonabant
November 5, 2008
Third-quarter 2008 results
October 31, 2008
New ADA/EASD treatment recommendations: timely use of basal insulin reinforced as a “Core Therapy” for type 2 diabetes
October 30, 2008
FDA approves rapid-acting insulin Apidra® for treatment of children with diabetes
October 29, 2008
High-dose influenza vaccine shows increased immune response among adults 65 years of age and older
October 26, 2008
Sanofi-aventis is complying with the EMEA’s recommendation to temporarily suspend the marketing authorisation of Acomplia® in obese and overweight patients
October 23, 2008
Sanofi-aventis and Medicines for Malaria Venture enter into collaboration to fight Malaria
October 22, 2008
Sanofi-aventis expands its R&D presence in China
October 21, 2008
Coarsucam™ (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO Prequalification
October 16, 2008
Sanofi-aventis enters into collaboration with TB Alliance to fight Tuberculosis
October 14, 2008
Sanofi-aventis signs a collaboration agreement with RainDance Technologies and Louis Pasteur University to launch dScreen Consortium within “Alsace BioValley” cluster
September 26, 2008
Sanofi Pasteur completes the acquisition of Acambis
September 25, 2008
FDA approves Nasacort AQ® nasal spray for children aged 2-5 years old
September 23, 2008
Sanofi-aventis strengthens its position in the Dow Jones Sustainability World Index
September 22, 2008
Sanofi-aventis announces intention to raise offer for Zentiva to CZK 1150 in cash per share
September 22, 2008
Sanofi-aventis europe’s offer for Zentiva NV to remain open until November 28, 2008
September 18, 2008
Multi-pronged therapeutic cancer vaccine regimen to be studied in melanoma patients
September 17, 2008
New study results support the “Basal Plus” strategy with LANTUS® and APIDRA® to improve blood sugar control in patients with type 2 diabetes
September 10, 2008
People with type 2 diabetes treated with LANTUS® and APIDRA® achieved greater reductions in A1C than those treated with pre-mixed insulin
September 10, 2008
Upcoming change of Chief Executive Officer
September 10, 2008
New real life studies illustrate greater A1C lowering and cost benefit observed with LANTUS® over detemir and NPH insulin
September 8, 2008
Inauguration of the sanofi-aventis Central Anti-Counterfeit Laboratory in Tours
September 4, 2008
Further analysis from ATHENA study showed that Multaq® (dronedarone) reduced the risk of stroke in patients with atrial fibrillation
September 3, 2008
Acambis’ shareholders approve Sanofi Pasteur Holding’s offer by a large majority
September 2, 2008
Sanofi-aventis acquisition of Symbion Consumer in Australia now completed
September 1, 2008
“Taxotere® Injection” (docetaxel hydrate) approved in Japan for the treatment of prostate cancer
September 1, 2008
Multaq® (dronedarone) granted FDA Priority Review for patients with atrial fibrillation
August 8, 2008
Sanofi Pasteur shipping first doses of influenza vaccine for the 2008-2009 season in the US
August 1, 2008
Availability on line of the Group’s half-year financial report for 2008
July 31, 2008
Second quarter 2008 results
July 31, 2008
Clopidogrel in Germany
July 29, 2008
Recommended Offer by Sanofi Pasteur for Acambis plc
July 25, 2008
European Commission approved APIDRA® for treatment of children & adolescents with diabetes
July 24, 2008
Newly published study results showed that two mealtime insulin dosing algorithms were effective for patients with type 2 diabetes
July 22, 2008
Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed dose combination ASAQ at equally low prices
July 21, 2008
Sanofi-aventis enters into agreement with Primary Health Care to acquire “Symbion Consumer”, its nutraceuticals & OTC division, in Australia
July 21, 2008
Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
July 18, 2008
Sanofi-aventis signs a collaboration agreement with The Johns Hopkins University School of Medicine to find new therapies for respiratory & immuno-allergic diseases
July 17, 2008
Publication of Sanofi-aventis Europe’s Offer of CZK 1,050 in cash per share for Zentiva N.V
July 11, 2008
Sanofi Pasteur inaugurates High Tech vaccine production facility to respond to soaring demand worldwide
June 25, 2008
U.S. FDA licenses Sanofi Pasteur’s new pediatric combination vaccine, Pentacel®
June 23, 2008
Sanofi-aventis intends to make a Competing Bid of CZK 1,050 in cash per share for Zentiva
June 18, 2008
Sanofi-aventis becomes a major partner in the biotechnology field in year leading to BIO 2008
June 17, 2008
Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpile
June 16, 2008
Ambien CR® improved insomnia and daily functioning in patients with co-morbid major depressive disorder
June 10, 2008
Acomplia (rimonabant) significantly improved glucose control in type 2 diabetes patients treated with insulin
June 10, 2008
Five-year safety study examines the effect of LANTUS® on the progression of retinopathy in people with type 2 diabetes
June 10, 2008
Study shows LANTUS® helped people living with type 2 diabetes reach the ADA’s recommended target for blood sugar control
June 7, 2008
Insulin Glulisine APIDRA® efficacy in the treatment of children and adolescents with type 1 diabetes
June 7, 2008
New diabetes compound AVE0010 showed clear dose response results with once-a-day injection in phase IIb study
June 7, 2008
Sanofi-aventis and Oxford BioMedica report encouraging Trovax® Phase II trial results in metastatic renal cancer
June 2, 2008
Statement on third-party clopidogrel applications in Germany
May 28, 2008
New Eloxatin® (oxaliplatin injection) prescribing information in the U.S includes six-year overall survival data
May 28, 2008
Node-negative early stage breast cancer patients benefit from Taxotere®-based chemotherapy
May 27, 2008
ATHENA Clinical Results with Dronedarone (Multaq®) Highlighted at the World Congress of Cardiology
May 21, 2008
Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology
May 21, 2008
Landmark ATHENA Study Findings With Multaq® (dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
May 15, 2008
District Court Decision affirmed in U.S. Lovenox® (enoxaparin sodium) patent infringement case
May 15, 2008
Sanofi-aventis Annual General Meeting
May 15, 2008
Plavix®(clopidogrel) in Germany
May 9, 2008
Encouraging first-quarter 2008 results - Further positive Phase III results for eplivanserin
April 30, 2008
U.S. Government accepts $192 million of Sanofi Pasteur H5N1 bulk vaccine antigen for pandemic stockpile
April 28, 2008
Malaria: strong partnerships aiming to benefit patients in Africa
April 22, 2008
Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global Health
April 15, 2008
Information available concerning the Ordinary General Meeting of May 14, 2008
April 10, 2008
NICE Recommends Acomplia® to be included in the NHS Guidance
March 26, 2008
Perioperative Eloxatin®-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
March 21, 2008
U.S. FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
March 13, 2008
Filing of the 2007 U.S. Form 20-F and French “Document de Référence” and Annual Financial Report
March 7, 2008
Sanofi-aventis Board of Directors
March 7, 2008
New 300mg loading dose tablet for Plavix® receives positive opinion from the European Committee for Medicinal Products (CHMP)
March 5, 2008
OneWorld Health, Amyris Biotechnologies and Sanofi-aventis Announce Development Agreement for Semisynthetic Artemisinin
March 3, 2008
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
February 26, 2008
FDA approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
February 19, 2008
Sanofi-aventis’ SoloSTAR® insulin pen for Lantus and Apidra receives the prestigious GOOD DESIGN Award
February 14, 2008
Sanofi Pasteur and Statens Serum Institut team up against Tuberculosis
February 14, 2008
Sanofi Pasteur files for European Approval of the first seasonal influenza vaccine delivered by intradermal microinjection
February 13, 2008
2007 earnings ahead of guidance - Sharp rise in proposed dividend
February 12, 2008
Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology"
February 12, 2008
"Pathways of Solidarity" - a book and an exhibition
February 7, 2008
"My child matters": 25 programmes in 16 countries to fight childhood cancers
February 4, 2008
Clexane®/Lovenox® approved in Japan
January 28, 2008
Ambien CR® (zolpidem tartrate extended-release) tablets CIV improved chronic insomnia in patients with co-morbid generalized anxiety disorder
January 4, 2008
Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against Rabies
January 3, 2008
|
|
